Bromodomain and extraterminal protein-targeted probe enables tumour visualisation

Humans Proteins Positron-Emission Tomography / methods Glioblastoma / diagnostic imaging Protein Domains

Journal

Chemical communications (Cambridge, England)
ISSN: 1364-548X
Titre abrégé: Chem Commun (Camb)
Pays: England
ID NLM: 9610838

Informations de publication

Date de publication:
09 Mar 2023
Historique:
pubmed: 23 2 2023
medline: 14 3 2023
entrez: 22 2 2023
Statut: epublish

Résumé

Bromodomain and extraterminal (BET) proteins, a family of epigenetic regulators, have emerged as important oncology drug targets. BET proteins have not been targeted for molecular imaging of cancer. Here, we report the development of a novel molecule radiolabelled with positron emitting fluorine-18, [

Identifiants

DOI: 10.1039/d2cc04813b PMID: 36809538
pubmed: 36809538
doi: 10.1039/d2cc04813b
doi:

Substances chimiques

Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3126-3129

Auteurs

Catherine G Fitzgerald Dickmann (CGF)

Bio21 Institute, The University of Melbourne, Parkville, VIC 3010, Australia. whitejm@unimelb.edu.au.
Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, and School of Cancer Medicine, La Trobe University, Heidelberg, Australia. uwea@unimelb.edu.au.
Department of Molecular Imaging and Therapy, Austin Hospital, Heidelberg, Australia.
ORCID: 0000-0002-8829-5354

Alexander F McDonald (AF)

Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, and School of Cancer Medicine, La Trobe University, Heidelberg, Australia. uwea@unimelb.edu.au.
Department of Molecular Imaging and Therapy, Austin Hospital, Heidelberg, Australia.
ORCID: 0000-0001-5261-8118

Nhi Huynh (N)

Department of Molecular Imaging and Therapy, Austin Hospital, Heidelberg, Australia.

Angela Rigopoulos (A)

Department of Molecular Imaging and Therapy, Austin Hospital, Heidelberg, Australia.

Zhanqi Liu (Z)

Department of Molecular Imaging and Therapy, Austin Hospital, Heidelberg, Australia.

Nancy Guo (N)

Department of Molecular Imaging and Therapy, Austin Hospital, Heidelberg, Australia.

Laura D Osellame (LD)

Department of Molecular Imaging and Therapy, Austin Hospital, Heidelberg, Australia.
ORCID: 0000-0001-6174-3797

Michael A Gorman (MA)

Bio21 Institute, The University of Melbourne, Parkville, VIC 3010, Australia. whitejm@unimelb.edu.au.
ORCID: 0000-0003-3438-8245

Michael W Parker (MW)

Bio21 Institute, The University of Melbourne, Parkville, VIC 3010, Australia. whitejm@unimelb.edu.au.
ACRF Facility for Innovative Cancer Drug Discovery, Bio21 Institute, The University of Melbourne, Parkville, VIC 3010, Australia.
ACRF Rational Drug Discovery Centre, St. Vincent's Institute of Medical Research, VIC 3065, Australia.
ORCID: 0000-0002-3101-1138

Hui K Gan (HK)

Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, and School of Cancer Medicine, La Trobe University, Heidelberg, Australia. uwea@unimelb.edu.au.
ORCID: 0000-0001-7319-8546

Andrew M Scott (AM)

Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, and School of Cancer Medicine, La Trobe University, Heidelberg, Australia. uwea@unimelb.edu.au.
Department of Molecular Imaging and Therapy, Austin Hospital, Heidelberg, Australia.
Faculty of Medicine, University of Melbourne, Parkville, Australia.
ORCID: 0000-0002-6656-295X

Uwe Ackermann (U)

Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, and School of Cancer Medicine, La Trobe University, Heidelberg, Australia. uwea@unimelb.edu.au.
Department of Molecular Imaging and Therapy, Austin Hospital, Heidelberg, Australia.
ORCID: 0000-0001-9259-2258

Ingrid J G Burvenich (IJG)

Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, and School of Cancer Medicine, La Trobe University, Heidelberg, Australia. uwea@unimelb.edu.au.
ORCID: 0000-0001-8384-2403

Jonathan M White (JM)

Bio21 Institute, The University of Melbourne, Parkville, VIC 3010, Australia. whitejm@unimelb.edu.au.
ORCID: 0000-0002-0707-6257

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Bromodomain and extraterminal protein-targeted...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Bromodomain and extraterminal protein-targeted...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › Bromodomain and extraterminal protein-targeted...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs du tissu nerveux › Tumeurs neuroectodermiques › Tumeurs neuroépitheliales › Gliome › Astrocytome › Glioblastome › Bromodomain and extraterminal protein-targeted...
questionsmedicales.fr › Phénomènes chimiques › Phénomènes biochimiques › Conformation moléculaire › Conformation des protéines › Structure tertiaire des protéines › Domaines protéiques › Bromodomain and extraterminal protein-targeted...